| 01/27 | Disappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre.. | MT |
| 01/27 | Biogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application f.. | MT |
| 01/27 | Samsung Biologics Plans to Build an ADC Manufacturing Suite in Plant 4 to Start Product.. | CI |
| 01/26 | Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization | DJ |
| 01/26 | Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Au.. | CI |
| 01/25 | Lonza underscores growth prospects with share buy-back, dividend hike | RE |
| 01/24 | Australian shares flat as miners offset gains in banks | RE |
| 01/24 | Morgan Stanley Adjusts Price Target on Biogen to $345 From $325, Maintains Overweight R.. | MT |
| 01/23 | Biogen Says US FDA Sets Advisory Committee Meeting in March for Tofersen | MT |
| 01/20 | Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts | RE |
| 01/17 | Eisai, Biogen Seek Approval for Alzheimer's Drug in Japan | MT |
| 01/17 | Trending: Wuxi Biologics Shareholder Plans Block Sale | DJ |
| 01/17 | Australia shares end marginally lower as commodities drag | RE |
| 01/17 | WuXi Biologics (Cayman) Substantial Shareholder to Place 56 Million Shares; Shares Slip.. | MT |
| 01/17 | Wuxi Biologics' Major Shareholder Plans to Sell 1.3% Stake | CI |
| 01/17 | Wuxi Biologics Drops After Major Shareholder Plans to Sell 1.3% Stake | DJ |
| 01/16 | Yen Boost, Prospect of Monetary Policy Shift Spook Japanese Traders; Daiichi Sankyo Fil.. | MT |
| 01/15 | Eisai files for approval of Alzheimer's drug in Japan | RE |
| 01/15 | Eisai files for approval of Alzheimer's drug in Japan | RE |
| 01/13 | RBC Trims Price Target on Biogen to $359 From $362, Maintains Outperform Rating | MT |
| 01/11 | U.S. to announce list of drugs for pricing negotiations Sept. 1 | RE |
| 01/11 | Biogen, Eisai Seek Marketing Clearance in Europe for Early Alzheimer's Disease Drug | MT |
| 01/10 | Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanem.. | CI |
| 01/09 | Transcript : Biogen Inc. Presents at 41st Annual J.P. Morgan Healthcare Confe.. | CI |
| 01/09 | Global markets live: Alibaba, Qiagen, Macy's, Oracle, Chevron... | |
| 01/09 | Trending: Biogen, Eisai Win FDA Nod for Alzheimer's Drug | DJ |
| 01/09 | Oppenheimer Adjusts Biogen's Price Target to $320 From $315, Maintains Outperform Ratin.. | MT |
| 01/09 | Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts | RE |
| 01/08 | Eisai, Biogen Get US Drug Regulator's Nod for Alzheimer's Drug | MT |
| 01/06 | Eisai files for full FDA approval for Alzheimer's drug Leqembi | RE |
| 01/06 | Wall St rallies as jobs, services data calm rate hike worries | RE |
| 01/06 | Biogen's Leqembi Alzheimer's Medication Gets US FDA Accelerated Approval | MT |
| 01/06 | Biogen's Leqembi Alzheimer's Medication Gets US FDA Accelerated Approval | MT |
| 01/06 | Biogen's Alzheimer's Drug Approved by FDA, Shares to Resume Trading | MT |
| 01/06 | Eisai says new Alzheimer's drug to cost $26,500 annually | RE |
| 01/06 | Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under th.. | CI |
| 01/06 | Biogen Shares Halted For Pending News Stock Up 3.6% Before Halt | MT |
| 01/06 | U.S. FDA approves Eisai, Biogen's Alzheimer's drug | RE |
| 01/05 | Biogen splits R&D division ahead of key decision on Alzheimer's drug | RE |
| 01/05 | SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Ant.. | CI |
| 01/05 | Biogen names Priya Singhal as head of development after splitting R&D division | RE |
| 01/05 | Biogen Names Priya Singhal as Executive Vice President, Head of Development | CI |
| 01/05 | U.S. new drug price exceeds $200,000 median in 2022 | RE |
| 01/05 | WuXi Biologics signs exclusive deal with GSK | AN |
| 01/05 | Trending: Wuxi Biologics Licenses Tumor Antibodies to GSK | DJ |
| 01/04 | Wuxi Biologics And Gsk Enter Into License Agreement On Multiple Novel Bi- & Multi-Speci.. | RE |
| 01/04 | Wuxi Biologics and GSK plc Enter into License Agreement on Multiple Novel Bi- & Multi-S.. | CI |
| 01/04 | Biogen, Alcyone Therapeutics to Collaborate on Medical Device to Deliver Antisense Olig.. | MT |
| 2022 | Biogen, FDA Interactions in Run-up to Aduhelm Approval Seen as 'Atypical,' US House Rep.. | MT |
| 2022 | U.S. FDA approves TG Therapeutics' multiple sclerosis drug | RE |
| 2022 | Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report | RE |
| 2022 | Biogen's Partner Eisai Begins Biologics License Application for Lecanemab in China | MT |
| 2022 | Japan drugmaker Eisai's shares slump after report of 3rd death in Alzheimer's trial | RE |
| 2022 | Sysmex says Japan approves blood test for Alzheimer's marker | RE |
| 2022 | Biogen, Genentech Enter Into Agreement on Royalties, Potential Marketing of Investigati.. | MT |
| 2022 | Biogen Inc. Reaches Agreement with Genentech to Receive Royalties on the Potential Comm.. | CI |
| 2022 | CSL Limited Announces Positive CHMP Opinion for Etranacogene Dezaparvovec – Gene T.. | CI |
| 2022 | China's Property Support Measures Propel Rebound in Hong Kong Stocks; Wuxi Biologics Ju.. | MT |
| 2022 | Wuxi Biologics Shares Gain After Unit's Removal From U.S. 'Unverified List' | DJ |
| 2022 | Chinese firms avert delisting as U.S. audit watchdog gets full inspection access | RE |
| 2022 | Insider Sell: Biogen | MT |
| 2022 | CSL Appoints CEO and Managing Director | MT |
| 2022 | Australian shares track Wall Street higher, focus on U.S. inflation data | RE |
| 2022 | CSL Limited Announces Chief Executive Officer Changes | CI |
| 2022 | CSL Limited Announces Management Changes | CI |
| 2022 | Australia's CSL Ltd names insider Paul McKenzie as CEO | RE |
| 2022 | CSL Appoints Chief Operating Officer as CEO, MD From March 2023 | DJ |
| 2022 | Csl Limited Announces That Its Subsidiary, Csl Seqirus Finalized Global Collaboration a.. | CI |
| 2022 | Trending : Biogen Application for Actemra Biosimilar Accepted for Review | DJ |
| 2022 | Correction to Biogen Actemra Biosimilar Article | DJ |
| 2022 | Biogen Says FDA Accepted Arthritis Drug Candidate Application for Review | MT |
| 2022 | Biogen: FDA Accepts Application for Actemra Biosimilar | DJ |
| 2022 | U.S. Food and Drug Administration Accepts Biogen Inc.'s Biologics License Application f.. | CI |
| 2022 | Immutep Achieves Commercial Scale Production of Immunotherapy Candidate | MT |
| 2022 | Biogen Inc., Sage Therapeutics, Inc. - Special Call | CI |
| 2022 | Sage Therapeutics, Biogen Complete Rolling Submission of New Drug Application for Zuran.. | MT |
| 2022 | Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zu.. | CI |
| 2022 | Ionis Pharmaceuticals Says European Medicines Agency Accepts Application to Review Expe.. | MT |
| 2022 | Biogen's Marketing Application for Tofersen Accepted for Review by European Medicines A.. | MT |
| 2022 | Biogen Says European Medicines Agency Accepts Marketing Authorization Application of To.. | MT |
| 2022 | Biogen Inc. Announces European Medicines Agency Accepts Tofersen Marketing Authorizatio.. | CI |
| 2022 | UGI Says Talks to Sell French Energy Marketing Business Discontinued But Exit Still Pla.. | MT |
| 2022 | Transcript : Biogen Inc. Presents at 5th Annual Evercore ISI HealthCONx Confe.. | CI |
| 2022 | Atlantic Equities Adjusts Price Target on Biogen to $295 From $220, Maintains Neutral R.. | MT |
| 2022 | UBS Adjusts Biogen Price Target to $338 From $319, Maintains Buy Rating | MT |
| 2022 | Analyst recommendations: Biogen, BAT, Hubbell, Liberty Global, P.. | |
| 2022 | Wall Street ends sharply higher after Powell comments | RE |
| 2022 | Wall Street ends sharply higher after Powell comments | RE |
| 2022 | Wall Street ends sharply higher after Powell comments | RE |
| 2022 | Wall Street rallies after Powell eyes slower rate hikes | RE |
| 2022 | Wall Street rises after Powell eyes slower rate hikes | RE |
| 2022 | Global markets live: Apple, Tesla, Boeing, HP, Intuit... | |
| 2022 | Trending: Eisai/Biogen Alzheimer's Drug Shows Positive Results | DJ |
| 2022 | Stifel Adjusts Price Target on Biogen to $331 From $299, Maintains Buy Rating | MT |
| 2022 | Jefferies Adjusts Price Target on Biogen to $350 From $325, Maintains Buy Rating | MT |
| 2022 | Wedbush Raises Biogen's Price Target to $247 From $218, Says Data Reinforces Likelihood.. | MT |
| 2022 | Barclays Raises Price Target on Biogen to $313 From $275, Keeps Equalweight Rating | MT |
| 2022 | Biogen, Eisai Say Lecanemab Reduces Clinical Decline in Early Alzheimer's Disease Phase.. | MT |
| 2022 | Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus | RE |
| 2022 | Japanese drugmaker Eisai's shares drop on report of death in Alzheimer's trial | RE |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
